NAUTILUS BIOTECHNOLOGY INC (NAUT)

US63909J1088 - Common Stock

2.69  +0.02 (+0.75%)

After market: 2.69 0 (0%)

Fundamental Rating

2

Taking everything into account, NAUT scores 2 out of 10 in our fundamental rating. NAUT was compared to 58 industry peers in the Life Sciences Tools & Services industry. NAUT has a great financial health rating, but its profitability evaluates not so good. NAUT is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

NAUT had negative earnings in the past year.
NAUT had a negative operating cash flow in the past year.
NAUT had negative earnings in each of the past 5 years.
NAUT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NAUT's Return On Assets of -23.37% is on the low side compared to the rest of the industry. NAUT is outperformed by 72.41% of its industry peers.
NAUT has a worse Return On Equity (-27.03%) than 60.34% of its industry peers.
Industry RankSector Rank
ROA -23.37%
ROE -27.03%
ROIC N/A
ROA(3y)-16.67%
ROA(5y)-24.08%
ROE(3y)-18.74%
ROE(5y)-25.85%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NAUT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

NAUT has about the same amout of shares outstanding than it did 1 year ago.
NAUT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 3.91 indicates that NAUT is not in any danger for bankruptcy at the moment.
NAUT has a better Altman-Z score (3.91) than 65.52% of its industry peers.
NAUT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.91
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 20.09 indicates that NAUT has no problem at all paying its short term obligations.
NAUT has a Current ratio of 20.09. This is amongst the best in the industry. NAUT outperforms 96.55% of its industry peers.
NAUT has a Quick Ratio of 20.09. This indicates that NAUT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 20.09, NAUT belongs to the best of the industry, outperforming 96.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 20.09
Quick Ratio 20.09

0

3. Growth

3.1 Past

The earnings per share for NAUT have decreased strongly by -19.57% in the last year.
EPS 1Y (TTM)-19.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to decrease by -15.72% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-45.15%
EPS Next 2Y-27.4%
EPS Next 3Y-15.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

NAUT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NAUT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

NAUT's earnings are expected to decrease with -15.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.4%
EPS Next 3Y-15.72%

0

5. Dividend

5.1 Amount

NAUT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NAUTILUS BIOTECHNOLOGY INC

NASDAQ:NAUT (5/3/2024, 7:08:09 PM)

After market: 2.69 0 (0%)

2.69

+0.02 (+0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap336.98M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.37%
ROE -27.03%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 20.09
Quick Ratio 20.09
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-19.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-45.15%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y